![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Under the collaboration, Umoja will leverage Ozette Endpoints™ and Ozette Discovery™ to enable both companies' multidisciplinary scientific and bioinformatic teams to collaborate and expand the benefits of CAR T-cell immunotherapy to patients in need.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Umoja Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 21, 2023